Digest Network Come funziona
Network
/
Società
Io
Non verificato

Io Therapeutics, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaMedicina Salute Benessere

7 comunicati stampa

Guarda tutti i comunicati
23/12/2024
Biotecnologia
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
11/12/2024
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
08/11/2024
Biotecnologia
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
18/09/2024
Biotecnologia
Medicina Salute Benessere
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
16/07/2024
Biotecnologia
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
09/07/2024
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0
08/07/2024
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Fonte
Io Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0